Cost-utility of NeuroSAFE-guided RARP Versus Standard RARP in Men with Localised Prostate Cancer in the UK.
- DOI
- 10.1016/j.euros.2026.08.007
- Published
- 2026 Oct
- Container
- European urology open science
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.euros.2026.08.007,
title = {Cost-utility of NeuroSAFE-guided RARP Versus Standard RARP in Men with Localised Prostate Cancer in the UK.},
author = {Wang J and Almeida-Magana R and Dinneen E and Pan S and Leurent B and Roberts N and Brew-Graves C and Williams NR and Haider A and Shaw G and Pizzo E},
year = {2026},
journal = {European urology open science},
doi = {10.1016/j.euros.2026.08.007},
url = {https://doi.org/10.1016/j.euros.2026.08.007}
}RIS
TY - JOUR TI - Cost-utility of NeuroSAFE-guided RARP Versus Standard RARP in Men with Localised Prostate Cancer in the UK. AU - Wang J AU - Almeida-Magana R AU - Dinneen E AU - Pan S AU - Leurent B AU - Roberts N AU - Brew-Graves C AU - Williams NR AU - Haider A AU - Shaw G AU - Pizzo E PY - 2026 JO - European urology open science DO - 10.1016/j.euros.2026.08.007 UR - https://doi.org/10.1016/j.euros.2026.08.007 ER -
APA
J, W., R, A., E, D., S, P., B, L., N, R., C, B., NR, W., A, H., G, S., & E, P. (2026). Cost-utility of NeuroSAFE-guided RARP Versus Standard RARP in Men with Localised Prostate Cancer in the UK.. European urology open science. https://doi.org/10.1016/j.euros.2026.08.007
Source records
- pubmed · retrieved 2026-09-25T23:56:27.100Z